Poland· PL-100432311
Beovu
A brolucizumab product containing brolucizumabum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Brolucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC S01LA06 (brolucizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Brolucizumab · ATC S01LA06
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Brolucizumabum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- S01LA06
- ATC class
- Brolucizumab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421034993
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Brolucizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBeovu 120 mg/mlNovartis Europharm
- CzechiaBEOVUNovartis Europharm Limited, Dublin
- IcelandBeovuNovartis Europharm Limited*
- SwedenBeovu 120 mg/ml Injektionsvätska, lösningNovartis Europharm Limited
- FranceBEOVU 120 mg/ml, solution injectable en seringue préremplieNOVARTIS EUROPHARM (IRLANDE)
- IrelandBeovu 120 mg/ml solution for injection in pre-filled syringeNovartis Europharm Limited
- SwitzerlandBeovu
- NetherlandsBeovu 120 mg/ml, oplossing voor injectieNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beovu
- Liechtenstein · Beovu
- Norway · Beovu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8555c998-44b8-4248-80ca-a9756a735ac8 GET /v1/drugs/8555c998-44b8-4248-80ca-a9756a735ac8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "120 mg/ml",
"packaging": "07613421034993 ¦ Rpz ¦ EU/1/19/1417/001 ¦ 135603\n1 amp.-strzyk. 0,165 ml\nRpz ¦ EU/1/19/1417/002 ¦ 135604\n1 fiol. 0,23 ml + 1 igła z filtrem",
"substance": "Brolucizumabum 120 mg/ml",
"common_name": "Brolucizumabum",
"pl_product_id": "100432311",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about brolucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.